Melanie Senior
Change of control clauses have always mattered in biopharmaceutical dealmaking. But these days, VCs are designing biotechs from scratch with...
Change of Control: Why Getting it Right Matters Even More
Private biotechs' growing dependence on an M&A exit and the more lively acquisition activity throughout the sector means change of control provisions are being far more heavily negotiated than in the past, and it's critical to understand how far-reaching these provisions could be for biotechs hoping for successful exits.
More from Business Strategy
• By
During Q2, biopharma merger and acquisition deal value reached $24.6bn and drew in $60.7bn in potential deal value from alliances. Device company M&A values reached $223m, while in vitro diagnostics and research tools players’ M&A activity totaled $802m.
• By
Pharma leaders are shifting from AI pilots to enterprise-scale deployment, favoring external partnerships for efficiency gains while maintaining tight control over sensitive clinical data.
• By
The biotech funding landscape is undergoing a fundamental shift. With traditional VC becoming increasingly cautious and selective, industry executives are exploring new avenues for capital. Conversely, this evolution may ultimately benefit the sector's long-term sustainability.
• By
In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.
More from In Vivo
• By
Tevard Biosciences CEO Daniel Fischer discusses how engineered suppressor tRNAs overcome nonsense mutations, restoring full-length protein production to treat rare genetic diseases like Dravet syndrome.
• By
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.